Hepatocyte growth factor is a better indicator of therapeutic response than C-reactive protein within the first day of treatment in pneumonia

Chemotherapy

Volumn 52, Issue 5, 2006, Pages 260-263

  Abednazari, Hossein ^a   Xu, Junyang ^a   Millinger, Eva ^a   Brudin, Lars ^b   Forsberg, Pia ^a   Nayeri, Fariba ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

C reactive protein; Hepatocyte growth factor; Pneumonia

Indexed keywords

C REACTIVE PROTEIN; CARBAPENEM; CEFOTAXIME; CEFUROXIME; PENICILLIN G; SCATTER FACTOR;

ACCURACY; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BODY TEMPERATURE MEASUREMENT; C REACTIVE PROTEIN BLOOD LEVEL; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HEPATOCYTE GROWTH FACTOR BLOOD LEVEL; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; C-REACTIVE PROTEIN; HEPATOCYTE GROWTH FACTOR; HUMANS; PNEUMONIA; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 33747841009     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094868     Document Type: Article

References (18)

1. Matsumoto K, Nakamura T: Hepatocyte growth factor: molecular structure and implications for a central role in liver regeneration. J Gastroenterol Hepatol 1991;6:509-519.
2. Wolf H, Zarnegar R, Michalopoulos GK: Localization of hepatocyte growth factor in human and rat tissues: an immunohistochemical study. Hepatology 1991;14:488-494.
3. Seki T, Ihara I, Sugimura A, Shimonishi M, Nishizawa T, Asamai O, Hagiya M, Nakamura T, Shimizu S: Isolation and expression of cDNA of different forms of hepatocyte growth factor from human leukocytes. Biochem Biophys Res Commun 1990;172:321-327.
4. Nayeri F, Nilsson I, Brudin L, Fryden A, Söderström C, Forsberg P: High hepatocyte growth factor levels in the acute stage of community-acquired infectious diseases. Scand J Infect Dis 2002;34:127-130.
5. Nayeri F, Millinger E, Nilsson I, Zetterström O, Brudin L, Forsberg P: Exhaled breath condensate and serum levels of hepatocyte growth factor in pneumonia. Resp Med 2002;96:115-119.
6. Nayeri F, Brudin L, Darelid J, Nilsson I, Fryden A, Söderström C, Forsberg P: Hepatocyte growth factor (HGF) may act as an early therapeutic predictor in pneumonia. Scand J Infect Dis 2002;34:500-504.
7. Nayeri F, Brudin L, Nilsson I, Forsberg P: Sample handling and stability of hepatocyte growth factor in serum during infection. Cytokine 2002;19:201-205.
8. Smith DL, Fehling PC: Reliability of infrared tympanic thermometry (ITT). Aviat Space Environ Med 1996;67:272-274.
9. Matsukawa T, Ozaki M, Hanagata K, et al: A comparison of four infrared tympanic thermometers with tympanic membrane temperature measured by thermocouples. Can J Anaesth 1996;43:1224-1228.
10. Gerald L, Mandell J, Bennett E, Dolin R: Principles and Practice of Infectious Diseases, ed 5. Philadelphia, Churchill Livingstone, 2000, vol 1, pp 604-607.
11. Clyne B, Olshaker JS: The C-reactive protein. J Emerg Med 1999;17:1019-1025.
12. Schofield K, Voulgari F, Gozzard D, Leyland M, Beeching N, Stuart J: C-reactive protein concentration as a guide to antibiotic therapy in acute leukaemia. J Clin Pathol 1982;35:866-869.
13. Ehl S, Gehring B, Pohlandt F: A detailed analysis of changes in serum C-reactive protein levels in neonates treated for bacterial infection. Eur J Pediatr 1999;158:238-242.
14. Lindbäck S, Hellgren U, Julander I, Hansson L: The value of C-reactive protein as a marker of bacterial infection in patients with septicaemia/endocarditis and influenza. Scand J Infect Dis 1989;21:543-549.
15. Reinert RR, Lutticken R, Reinert S, Al-Lahham A, Lemmen S: Antimicrobial resistance of Streptococcus pneumoniae isolates of outpatients in Germany, 1999-2000. Chemotherapy 2004;50:184-189.
16. Reinert RR, Rodloff AC, Halle E, Baer W, Beyreiss B, Seifert H, Wichelhaus TA, Maass M, Mehl M: Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the ketolide telithromycin: results from the PROTEKT surveillance study (1999-2000). Chemotherapy 2004;50:143-151.
17. Liu K, Kato Y, Narukawa M, Kim DC, Hanano M, Higuchi O, Nakamura T, Sugiyama Y: Importance of liver in plasma clearance of hepatocyte growth factor in rats. Am J Physiol 1992;263:G642-G649.
18. Zioncheck T, Richardson L, DeGuzman G, Modi N, Hansen S, Godowski P: The pharmacokinetics, tissue localization and metabolic processing of recombinant human hepatocyte growth factor after intravenous administration in rats. Endocrinology 1994;134:1879-1887.